Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 110 Matches

EsomeprazoleCapsule_V14R1_AstraZeneca_20200427
https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.905 Esomeprazole adult compound file for pediatric prediction. The following parameters need to be updated, as compared to Table 2 in the manuscript: Ka=1.331/h, tlag=1h, fu,gut=0.048
Pemigatinib_V19R1_Incyte_20220114
A Pemigatinib PBPK article accepted by CPT PSP with leading author as Tao Ji The submitted workspace files for Pemigatinib is using minimal PBPK model with ADAM functions for Pemigatinib that incorporates CYP3A4-mediated metabolism derived from in vitro data, mass balance data, and clinical PK data, for the purpose of evaluation of clinical DDIs with strong CYP3A inhibitors and/or inducers.
Carboxyprimaquine

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

Related Files:  Primaquine (parent)

The model at-a-glance

  Absorption Model

N/A

  Volume of Distribution

Full PBPK (Method 2)

  Route of Elimination

  • Formed from primaquine by MAO. This is entered as ‘user-UGT’ as a surrogate within the simulator
  • Pathway of elimination is not defined; elimination is assigned as IV clearance that was manually optimized to fit the clinical data

  Perpetrator DDI

  • None

  Validation

  • Six clinical studies describing single and multiple dose exposure of carboxyprimaquine were used to verify the PBPK model.  The AUC for all verification studies were within 1.5-fold of the observed values.

  Limitations

  • Clinical data for carboxyprimaquine is highly variable

  Updates in V19

  • Converted from minimal PBPK model to full PBPK model

 

Tafenoquine

Brand Name(s) include: Arakoda, Krintafel

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

The model at-a-glance

  Absorption Model

  • First-Order

  Volume of Distribution

  • Full PBPK (Method 3)
  • Note: Kp scalar used

  Route of Elimination

  • Undefined liver intrinsic clearance

  Perpetrator DDI

  • CYP2C9 Inhibitor
  • CYP3A4 Inhibitor

  Validation

  • Four clinical studies describing single and multiple dose exposure of tafenoquine were used to verify the PBPK model, although some of these provided PK profiles and no PK parameters and vice versa.  Of the clinical studies describing PK parameters, the model recovered 100% of the observed PK parameters within 1.5-fold (66% within 0.8-1.25-fold) and hence the model is considered predictive.  

  Limitations

  • Tafenoquine is administered with food to increase its exposure and minimize gastrointestinal side effects. The PBPK model was therefore developed to recover the PK of tafenoquine in the fed state.
  • It should be noted that in the absence of information defining the fm of drug metabolizing enzymes, an undefined liver intrinsic clearance is used in the model and hence the model is not able to simulate the liability of tafenoquine as a victim of DDIs.

 

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|